EAM
JNCE

Erste Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Erste Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,559,587
Closed -$2.89M – 609
2023
Q1 		$2.89M Buy
1,559,587
+100,000
+7% +$124K 0.06% 258
2022
Q4 		$1.62M Buy
1,459,587
+610,000
+72% +$868K 0.03% 298
2022
Q3 		$1.98M Hold
849,587
– – 0.04% 282
2022
Q2 		$2.57M Buy
849,587
+80,000
+10% +$389K 0.06% 264
2022
Q1 		$5.23M Buy
769,587
+40,000
+5% +$285K 0.1% 213
2021
Q4 		$5.92M Sell
729,587
-50,000
-6% -$412K 0.11% 193
2021
Q3 		$5.79M Buy
779,587
+120,000
+18% +$743K 0.11% 181
2021
Q2 		$4.47M Buy
659,587
+25,000
+4% +$208K 0.09% 215
2021
Q1 		$6.49M Buy
634,587
+50,000
+9% +$548K 0.16% 160
2020
Q4 		$3.9M Hold
584,587
– – 0.11% 191
2020
Q3 		$4.77M Buy
584,587
+30,000
+5% +$186K 0.16% 150
2020
Q2 		$3.83M Sell
554,587
-50,000
-8% -$270K 0.15% 151
2020
Q1 		$2.87M Sell
604,587
-68,100
-10% -$392K 0.17% 150
2019
Q4 		$5.47M Buy
672,687
+40,000
+6% +$216K 0.24% 105
2019
Q3 		$2.11M Buy
632,687
+25,000
+4% +$100K 0.11% 180
2019
Q2 		$3M Buy
607,687
+39,000
+7% +$207K 0.16% 137
2019
Q1 		$3.52M Buy
568,687
+258,587
+83% +$1.25M 0.2% 125
2018
Q4 		$1.04M Buy
+310,100
New +$1.45M 0.07% 232

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Erste Asset Management's JNCE Position: Q2 2023 in Review

Erste Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 1,559,587 shares — an estimated $2.89M sold.

Erste Asset Management first reported a position in JNCE in Q4 2018 and held it in 18 quarters. The position peaked at $6.49M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Erste Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Erste Asset Management sold 1,559,587 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.89M.
  • Erste Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and held it in 18 quarters.
  • Erste Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $6.49M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Erste Asset Management's 13F filing for Q2 2023, filed 26 Nov 2024.